´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2022 Semi-annual Meeting : 2022-05-14±³À°ÀÏÀÚ : 2022-05-14
±³À°Àå¼Ò : Bexco
±³À°ÁÖÁ¦ :
KGOG 2022 Semi-annual MeetingÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420
À̸ÞÀÏ :
kiskgog@hanmail.net ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 7 ½Ã°£ 11ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 08:30~08:35 Ovary, Introduction/Review of on-going studies °¼®¹ü(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 08:35~08:39 Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (KGOG 3062 OV-HIPEC2) ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 08:39~08:43 Niraparib with or without bevacizumab in maintenance after complete cytoreduction in patients with ovarian cancer ( KGOG 3063 NIRVANA-1) ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 08:43~08:51 Phase II trial evaluation the Efficacy and safety of physician chosen Chemotherapy À̹æÇö(ÀÎÇϴ뺴¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 08:51~09:21 A Phase 3 multicenter study on the additional effect of stereotactic body radiation ±è¿ë¹è(¼¼ºê¶õ½ºº´¿ø)
Åä·Ð 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 09:21~09:31 discussion ±è¹Ì°æ(ÀÌ´ë¸ñµ¿º´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 09:31~10:01 Fatal toxicity of PARPi maintenance of ovarian cancer: How do we offer appropriate monitoring and investigation? Á¤±â¼±(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 10:20~10:23 Cervix, Vulva, Vagina Committee-Introduction À̱ÙÈ£(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 10:23~10:28 Overview of ongoing study Á¤¿ë¿í(°³²Â÷º´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 10:28~10:33 KGOG1043/A randomized, open-label phase 3 trial of Tisotumab vedotin Vs. investigator¡¯s choice chemotherapy in second or third line recurrent or metastatic cervical cancer À̼ºÁ¾(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 10:33~10:38 KGOG1044/Feasibility of HPV DNA and vaginal infectious disease detection in mail-delivered self obtained vaginal sample obtained by G+kit (SELPAX-I) ±è¹®È«(¿øÀڷº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 10:38~10:43 KGOG1046/Adjuvant chemotherapy versus radiotherapy for postoperative cervical cancer: A phase 3 trial (AFTER) ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 10:43~10:48 KGOG1047/Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIICr. A phase III, randomized controlledclinical trial (DEBULK trial) ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 10:48~11:03 Special Lecture I : Consideration when conduct clinical trials of gynecologic cancer as TBD()
Åä·Ð 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 11:03~11:05 discussion À±º¸¼º(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 11:05~11:15 COnization Before minimally invasive RAdical hysterectomy in 2018 FIGO stage IB1 cervical cancer (COBRA-1) À̸¶¸®¾Æ(¼¿ï´ëº´¿ø)
Åä·Ð 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 11:15~11:20 discussion ¹éÁöÈì(¾ÆÁִ뺴¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 11:20~11:30 The comparison of proportion of positive resection margin by use of Lugol¡¯s solution during LEEP and the identifications of predictors for residual tumor: A phase III, randomized controlled trial (Lugol trial) ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
Åä·Ð 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 11:30~11:35 discussion Á¶»óÇö(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 11:35~12:05 Special Lecture II : Introduction of Silva Pattern in Endocervical Adenocarcinoma as an important determinant for pelvic lymph node dissection ±è±Ô·¡(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 12:10~12:20 20 years history of KGOG ¹Î°æÁø(°í´ë¾È»êº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 12:20~12:30 Renewal homepage of KGOG ¼ÛÀçÀ±(°í´ë¾È¾Ïº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 12:30~12:50 Cutting-edge front-line maintenance therapy in BRCAm ovarian cancer – SOLO-1 ¹éÀ̼±(°ºÏ»ï¼ºº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 12:50~13:10 The Era of precision medicine with Olaparib and bevacizumab as frontline maintenance ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
Åä·Ð 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 13:10~13:20 Discussion ()
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 13:30~13:31 Surgery Committee-Introduction ÀÌÀºÁÖ(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 13:31~13:36 KGOG 4004 (OVsurg-2102-1): A survey on peritonectomy procedure in debulking operation of advanced ovarian, fallopian, peritoneal cancer ±è¸í¼±(¼ººó¼¾Æ®º´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 13:36~13:41 KGOG 4005 (OVsurg-2101): The analysis of the patients who have received reoperation whining 30 days after debulking operation for primary advanced epithelial ovarian, tubal, peritoneal cancer ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 13:41~13:45 OVsurg-2103: The analysis of 90-day postoperative mortality after debulking operation for primary advanced epithelial ovarian, tubal, peritoneal cancer ¼Û¿ëÁß(¾ç»êºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 13:45~13:50 OVsurg-2108: Assessment of QoL after LAR or visceral peritoneal stripping during cytoreductive surgery for AEOC: prospective cohort study (LAPSODY) trial ¹Ú¼öÁø(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 13:50~13:55 OVsurg-2106: Selection Criteria for Omitting Interval debulking surgery after neoadjuvant chemotherapy for high grade serous carcinoma of the ovary (SCORE study) ÀÌÀ¯¿µ(»ï¼º¼¿ïº´¿ø)
Åä·Ð 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 13:55~14:00 discussion ()
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 14:00~14:05 Surgical Treatment of lymphedema ÀÌÁؼ®(°æºÏ´ëº´¿ø¼ºÇü¿Ü°ú)
Åä·Ð 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 14:05~14:10 discussion ()
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 14:30~14:33 Rare Tumor Committee-Introduction ÃÖöÈÆ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 14:33~14:53 Stratified mucin-producing intraepithelial lesion (SMILE) and invasive stratified mucin ±èÇö¼ö(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 14:53~14:58 Optimized therapeutic strategy for recurrent ovarian clear cell carcinoma with ARID1A status (OTC) ±èÅÂÀº(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 14:58~15:03 Clinical characteristics and prognosis in HPV independent cervical adenocarcinoma ÀåÇϱÕ(°í´ë¾È»êº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:03~15:08 Radical vs. fertility sparing surgery in intraepithelial mucinous carcinoma of ovary ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:08~15:10 MIS vs. open surgery in rare histology cervical cancer ±è¼¼ÀÍ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:10~15:12 A MRI-based machine learning approach for distinguishing uterine sarcoma leiomyomas ±èÅÂÈÆ(º¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:12~15:14 BRCA status in epithelial ovarian cancer with other than serous and endometrioid adenocarcinoma ±èÅÂÈÆ(º¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:14~15:19 Accuracy of cytology (PAP) in HPV independent cervical cancer ÀåÁö¼±(»ï¼º¼¿ïº´¿ø)
Åä·Ð 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:19~15:24 discussion ()
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:40~15:41 Uterine corpus-GTT committee introduction ±è¹Î±Ô(»ï¼ºÃ¢¿øº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:41~15:46 Review of ongoing study Active: 2020,2021(TREE PRO),2022(NRG GY018), À̸¶¸®¾Æ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:46~15:51 Progress of proposed studies À̸¶¸®¾Æ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:51~15:56 : Radical hysterectomy in Endometrial cancer with Cervical involvemENT (RECENT) ±è¼º¹Î(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 15:56~16:01 Characteristics, risk factors, and prognosis of incidentally diagnosed uterine neoplasms: a multi-institutional review study ¹é¹ÎÇö(ÇѸ²´ë¼º½Éº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 16:01~16:06 : Prevalence and clinical characteristics of endometrial cancer by molecular classification in Korean patients ÇÑ°üÈñ(°µ¿°æÈñ´ëº´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 16:06~16:11 Integrated genomic characterization of advanced endometrial cancer: KGOG consortium study ±è¹Ì°æ(ÀÌ´ë¸ñµ¿º´¿ø)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 16:11~16:31 Androgen therapy Clinical Trial for Uterine Cancer Katherine Kurnit(University of Chicago)
±³À°½Ã°£ 05-14 Á¦1Àü½Ã½Ç 3ÃþȸÀÇÀå 16:31~16:51 Clinical Trial Suggestion for Gestational Trophoblastic Neoplasia Neil S. Horowitz(Brigham & Women¡¯s Hospital/Dana Faber Cancer Institute)